Overview

Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan olanzapine 20 mg tablets to Eli Lilly Zyprexa® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Olanzapine